Mark Lovell, Ph.D. develops technology for a computerized neurocognitive test, which becomes the basis for his company, Neurohealth.
Dr. Lovell joins the Henry Ford Health System in Detroit as a neuropsychologist, where he meets Michael “Micky” Collins, Ph.D. He continues to work on the Neurohealth tests in his free time.
Dr. Collins joins Dr. Lovell at Neurohealth while continuing his work at the Henry Ford Health System. They conduct research studies at Michigan State University and at several high schools in the Detroit area on their technology which will be the foundation of ImPACT (Immediate Post-Concussion Assessment and Cognitive Test).
Dr. Lovell moves to Pittsburgh where he is named founding director of the University of Pittsburgh Medical Center (UPMC) Sports Medicine Concussion Program.
Dr. Collins joins him to become executive director of the UPMC Sports Medicine Concussion Program. They continue to develop their neurocognitive testing technology separate from their duties at UPMC.
Dr. Lovell and Dr. Collins continue gathering data on the neurocognitive effects of head injuries using the ImPACT technology, working with Dr. Joseph Maroon, co-medical director at UPMC and team neurosurgeon for the Pittsburgh Steelers.
Dr. Collins and Dr. Lovell officially incorporate Neurohealth as ImPACT Applications, Inc. with Dr. Lovell as CEO. The first product, ImPACT, is officially released.
ImPACT Applications, Inc. forms a partnership with Major League Soccer to use ImPACT, marking the company’s first professional sports customer.
ImPACT Applications, Inc. forms a strategic alliance with US Lacrosse to launch a formal concussion management program for lacrosse players using ImPACT for baseline and post-injury testing.
NASCAR becomes a customer of ImPACT Applications, Inc.
ImPACT Applications, Inc. marks the administration of its one millionth test.
1 million tests
The Chicago Blackhawks, in conjunction with the Amateur Hockey Association of Illinois (AHAI), Athletico Physical Therapy, and NorthShore University HealthSystem, launch the ‘A Step aHead’ concussion awareness initiative, offering complimentary ImPACT baselines to all AHAI members ages 13-18.
ImPACT Applications, Inc. introduces three new concussion management mobile apps: PCSI™ (Post-Concussion Symptom Inventory), Sideline ImPACT®, and Mobile ImPACT Customer Center (MICC).
ImPACT Applications, Inc. introduces the ImPACT Trained Athletic Trainers (ITAT) credentialing program, presenting athletic trainers a new opportunity to become leaders in concussion management.
ImPACT Applications, Inc. marks the administration of its five millionth test.
5 million tests
Fast Company Magazine names ImPACT Applications, Inc. no. 7 among the world’s 10 most innovative health care companies.
Lifemark Canada becomes a customer of ImPACT Applications.
ImPACT Applications, Inc. launches ImPACT Passport, giving trained healthcare professionals the ability to offer the free mobile app to patients and to access test takers’ ImPACT results and reported symptoms.
ImPACT Applications, Inc. partners with University Hospitals Case Medical Center to offer a comprehensive concussion management program.
NASCAR begins mandating baseline concussion testing using ImPACT.
ImPACT Applications, Inc. receives ISO 13485 certification.
ImPACT and ImPACT Pediatric obtains CE Marking and is registered in the EU to comply with European Medical Device Directive.
University of St. Augustine for Health Sciences becomes the first institution of higher learning to incorporate ImPACT Trained Athletic Trainer (ITAT) credentialing into the curriculum of its online Master of Health Science in Athletic Training degree program.
ImPACT Applications, Inc. launches ImPACT Workplace, a neurocognitive assessment product for businesses, corporations, and occupational medicine designed to provide employers, healthcare providers, and wellness professionals with an empirically-validated, reliable, and valid procedure for evaluating the neurocognitive status of their employee or patient.
Premier Health becomes a customer of ImPACT Applications, Inc.
ImPACT and ImPACT Pediatric receives Class II medical device license from Health Canada.
ImPACT Applications, Inc. receives the Bronze Award at the 2015 Edison Awards in testing and evaluation.
ImPACT Applications, Inc. marks the administration of its ten millionth test.
10 million tests
ImPACT Applications, Inc. is selected by New York Schools Insurance Reciprocal (NYSIR) to support its Head Injury Prevention Program.
ImPACT Applications, Inc. completes a SOC 2 Type 2 audit in accordance with AICPA Standards for the Security, Availability and Privacy Trust Service Criteria.
ImPACT Applications, Inc. becomes a registered medical device in Australia by receiving Medical Device Establishment License from Australian Therapeutic Goods Administration.
Formula 1 Racing selects ImPACT as part of its concussion management protocol for all drivers.
Technavio names ImPACT Applications, Inc. among its top seven leading vendors in its report highlighting the cognitive test and assessment market in Europe.
The UK-based Football Association, the governing body of football (soccer), partners with ImPACT Applications, Inc. to conduct baseline and post-injury neurocognitive testing using ImPACT and ImPACT Pediatric as part of its larger concussion management protocol. Begins testing of its women’s national teams that month.
ImPACT becomes the first concussion-specific medical device to receive FDA de novo clearance under Computerized Cognitive Assessment Aid for Concussion, a new category for a device that uses an individual's score(s) on a battery of cognitive tasks to provide an indication of the current level of cognitive function in response to concussion.
ImPACT Applications, Inc. marks the administration of its twelve millionth test.
12 million tests
ImPACT Applications, Inc. launches ImPACT Pediatric®, the first concussion management tool designed for individuals ages 5-11. ImPACT Pediatric also earns FDA clearance as a Computerized Cognitive Assessment Aid for Concussion.
ImPACT and ImPACT Pediatric receive regulatory clearance by ANVISA (Brazil).
February 2017ImPACT Applications, Inc. obtains FDA 510(k) clearance on the HTML5 version of ImPACT.
February 2017ImPACT Applications launches the HTML5 version of its Customer Center and of ImPACT allowing the medical device to operate across multiple web browsers and reduce ImPACT Applications’ support obligations.
March 2017ImPACT Quick Test becomes a registered medical device in the European Union by receiving CE Marking.
ImPACT Applications, Inc. marks the administration of its fourteen millionth test.
14 million tests
June 2017ImPACT Quick Test obtains FDA clearance for marketing in the US.
ImPACT Applications, Inc. marks the administration of its sixteen millionth test.
16 million tests
ImPACT Applications, Inc. offers the FDA cleared ImPACT Baseline Test to home-based users worldwide.
- Jan 14, 2020
Alpine Investors' Riverside Insights Acquires ImPACT Applications, Inc.
- Mar 27, 2020